Kadcyla breast cancer drug

Kadcyla breast cancer drug

C020/8800 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 50.1MB

Downloadable file size: 1.5MB

Price image Pricing

Please login to use the price calculator

This image is part of the feature B B C


Restrictions: Editorial use only

Caption: Kadcyla breast cancer drug. Packet of the anti-cancer drug trastuzumab emtansine, marketed by Roche under the trade name Kadcyla. This drug is an antibody-drug conjugate (ADC) with an antibody linked to a drug that kills the cancer cells targeted by the antibody. In this case, the conjugate is of trastuzumab (Herceptin) linked to the cytotoxic chemical mertansine (DM1). Herceptin targets the HER2 receptor in breast cancer. Trastuzumab emtansine was developed by Genentech and approved for use in the USA in 2013. Photographed in 2014.

Release details: Model release not required. Property release not available.

Keywords: 100mg, 2014, 21st century, adc, adult, anti-cancer, antibody-drug conjugate, breast cancer, caucasian, cytotoxic, dm1, doctor, drug, genetech, hand, healthcare, her2, herceptin, holding, human, intravenous use, kadcyla, medical, medication, medicine, mertansine, nurse, oncological, oncology, one person, packaging, packet, people, person, pharmaceutical, pharmaceutics, pharmacist, pharmacological, pharmacology, physician, powder, roche, trastuzumab emtansine, treatment, white

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.